İnfertilite Tedavisinde Kullanılan Farmakolojik Ajanlar
Özet
İnfertilite tedavisinde, hastanın hormonal aksındaki dengesizlikleri gidermek ve normal fizyolojisini yeniden düzenlemek amacıyla çeşitli farmakolojik ajanlar kullanılmaktadır. Yardımcı üreme teknikleri ve özellikle tüp bebek (IVF) süreçlerinde oosit indüksiyonu, uterusun hazırlanması ve spermatogenezin başlatılması için ilaç protokolleri uygulanır. Birinci basamak ovulasyon indüksiyon ajanı olan klomifen sitrat, östrojenik ve antiöstrojenik özelliklere sahip seçici bir östrojen reseptör modülatörüdür. Benzer yapıdaki tamoksifen ise klomifen sitrata alternatif olarak ovulasyon indüksiyonunda ve erkek infertilitesinde etiket dışı tercih edilmektedir. İnsülin sensitizörü olan metformin, polikistik over sendromlu (PKOS) obez kadınlarda insülin direncini azaltarak androjen seviyelerini iyileştirir ve tek başına veya klomifen sitratla kombine edilerek birinci basamak tedavide yer alır. Aromataz inhibitörlerinden letrozol, PKOS'lu hastalarda monofoliküler ovulasyonu uyarmada klomifenden daha etkili bir oral ajan olarak öne çıkmaktadır. Doğal bir şeker alkolü olan inositol, hücre içi sinyal molekülü olarak ovaryum fonksiyonunu destekler ve gebelikte gestasyonel diyabet riskini azaltır. Gonadotropin tedavisi, klomifen direncine sahip PKOS'lu kadınlarda ikinci basamak olarak insan idrarı türevli veya rekombinant formülasyonlarla (FSH ve LH) uygulanır. Oral kontraseptifler ise PKOS'ta androjen üretimini baskılamak ve endometriozis semptomlarını yönetmek amacıyla ampirik tedavi olarak yaygın bir şekilde tercih edilmektedir.
In infertility treatment, various pharmacological agents are utilized to rectify imbalances in the patient's hormonal axis and reorganize normal physiology. In assisted reproductive techniques, especially in IVF processes, regular drug protocols are administered for oocyte induction, preparing the uterus for implantation, and initiating spermatogenesis. Clomiphene citrate, a first-line ovulation induction agent, is a selective estrogen receptor modulator with both estrogenic and antiestrogenic properties. Tamoxifen, which is chemically similar, is recommended as an alternative for ovulation induction and used off-label in male infertility. Metformin, an insulin sensitizer, addresses insulin resistance in obese women with PCOS to improve androgen levels, serving as a first-line therapy either alone or combined with clomiphene. Among aromatase inhibitors, letrozole stands out as a more effective oral agent than clomiphene for inducing monofollicular ovulation in PCOS patients. Inositol, a naturally occurring sugar alcohol acting as an intracellular signaling molecule, supports ovarian function and reduces gestational diabetes risk during pregnancy. Gonadotropin therapy serves as a second-line treatment using urinary or recombinant formulations (FSH and LH) for women with clomiphene-resistant PCOS. Lastly, oral contraceptives are widely preferred as a primary or empirical treatment to suppress androgen production in PCOS and manage suspected endometriosis.
Referanslar
Xu, X.L., S.L. Deng, Z.X. Lian, et al. Estrogen Receptors in Polycystic Ovary Syndrome. Cells, 2021; 10(2). DOI: 10.3390/cells10020459.
Liao, Y., Y.K. Chang, S.M. Wang, et al. Ceiling effect of clomiphene citrate on the testosterone to estradiol ratio in eugonadal infertile men. PLoS One, 2022; 17(1); e0262924. DOI: 10.1371/journal.pone.0262924.
Collee, J., M. Mawet, L. Tebache, et al. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol, 2021; 37(10); 869-874. DOI: 10.1080/09513590.2021.1958310.
Earl, J.A. and E.D. Kim. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab, 2019; 14(3); 157-165. DOI: 10.1080/17446651.2019.1612239.
Helo, S., J. Mahon, J. Ellen, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU Int, 2017; 119(1); 171-176. DOI: 10.1111/bju.13625.
Kim, E.D., A. McCullough and J. Kaminetsky. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int, 2016; 117(4); 677-85. DOI: 10.1111/bju.13337.
Carrasquillo, R., K. Chu and R. Ramasamy. Novel Therapy for Male Hypogonadism. Curr Urol Rep, 2018; 19(8); 63. DOI: 10.1007/s11934-018-0816-x.
Adashi, E.Y. Clomiphene citrate: mechanism(s) and site(s) of action--a hypothesis revisited. Fertil Steril, 1984; 42(3); 331-44. DOI: 10.1016/s0015-0282(16)48069-6.
Wheeler, K.M., D. Sharma, P.K. Kavoussi, et al. Clomiphene Citrate for the Treatment of Hypogonadism. Sex Med Rev, 2019; 7(2); 272-276. DOI: 10.1016/j.sxmr.2018.10.001.
Liu, Y., Q. Chen, S. Yu, et al. Progestin-primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: A prospective randomized controlled trial. Clin Endocrinol (Oxf), 2018; 88(3); 442-452. DOI: 10.1111/cen.13532.
Von Hofe, J. and G.W. Bates. Ovulation induction. Obstet Gynecol Clin North Am, 2015; 42(1); 27-37. DOI: 10.1016/j.ogc.2014.09.007.
Mbi Feh, M.K. and R. Wadhwa, Clomiphene, in StatPearls. 2022: Treasure Island (FL).
Davidson, R., T. Motan and C. Korownyk. Clomiphene for anovulatory infertility. Can Fam Physician, 2016; 62(6); 492.
Jones, T., J.R. Ho, M. Gualtieri, et al. Clomiphene Stair-Step Protocol for Women With Polycystic Ovary Syndrome. Obstet Gynecol, 2018; 131(1); 91-95. DOI: 10.1097/AOG.0000000000002418.
Solipuram, V., K. Pokharel and T. Ihedinmah. Pulmonary Embolism as a Rare Complication of Clomiphene Therapy: A Case Report and Literature Review. Case Rep Endocrinol, 2021; 2021; 9987830. DOI: 10.1155/2021/9987830.
Sharma, S., M. Choudhary, V. Swarankar, et al. Comparison of Tamoxifen and Clomiphene Citrate for Ovulation Induction in Women with Polycystic Ovarian Syndrome: A Prospective Study. J Reprod Infertil, 2021; 22(4); 274-281. DOI: 10.18502/jri.v22i4.7653.
Williamson, J.G. and J.D. Ellis. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw, 1973; 80(9); 844-7. DOI: 10.1111/j.1471-0528.1973.tb11230.x.
Wibowo, E., P.A. Pollock, N. Hollis, et al. Tamoxifen in men: a review of adverse events. Andrology, 2016; 4(5); 776-88. DOI: 10.1111/andr.12197.
Bennett, W.L., H.E. Aschmann, M.A. Puhan, et al. A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol, 2019; 113; 92-100. DOI: 10.1016/j.jclinepi.2019.03.014.
Costello, M.F. and J.A. Eden. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril, 2003; 79(1); 1-13. DOI: 10.1016/s0015-0282(02)04554-5.
Cirillo, F., C. Catellani, P. Lazzeroni, et al. MiRNAs Regulating Insulin Sensitivity Are Dysregulated in Polycystic Ovary Syndrome (PCOS) Ovaries and Are Associated With Markers of Inflammation and Insulin Sensitivity. Front Endocrinol (Lausanne), 2019; 10; 879. DOI: 10.3389/fendo.2019.00879.
Bargiota, A. and E. Diamanti-Kandarakis. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab, 2012; 3(1); 27-47. DOI: 10.1177/2042018812437355.
Costello, M.F. and W.L. Ledger. Evidence-based lifestyle and pharmacological management of infertility in women with polycystic ovary syndrome. Womens Health (Lond), 2012; 8(3); 277-90. DOI: 10.2217/whe.12.14.
Costello, M.F., M.L. Misso, A. Balen, et al. A brief update on the evidence supporting the treatment of infertility in polycystic ovary syndrome. Aust N Z J Obstet Gynaecol, 2019; 59(6); 867-873. DOI: 10.1111/ajo.13051.
Quaas, A.M. and R.S. Legro. Pharmacology of medications used for ovarian stimulation. Best Practice & Research Clinical Endocrinology & Metabolism, 2019; 33(1); 21-33.
Turkistani, A. and S. Marsh. Pharmacogenomics of third-generation aromatase inhibitors. Expert Opin Pharmacother, 2012; 13(9); 1299-307. DOI: 10.1517/14656566.2012.687721.
Tannus, S., Y.Z. Burke and S. Kol. Treatment strategies for the infertile polycystic ovary syndrome patient. Womens Health (Lond), 2015; 11(6); 901-12. DOI: 10.2217/whe.15.40.
Kathrins, M. and C. Niederberger. Diagnosis and treatment of infertility-related male hormonal dysfunction. Nat Rev Urol, 2016; 13(6); 309-23. DOI: 10.1038/nrurol.2016.62.
Barwal, T.S., U. Sharma, S. Bazala, et al. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers. Int J Mol Sci, 2021; 22(8). DOI: 10.3390/ijms22084072.
Abbasalizadeh, F., F. Sahhaf, P. Sadeghi-Shabestari, et al. Comparison between effect of letrozole plus misoprostol and misoprostol alone in terminating non-viable first trimester pregnancies: a single blind randomized trial. Journal of Family & Reproductive Health, 2018; 12(1); 27.
Pritts, E.A. Letrozole for ovulation induction and controlled ovarian hyperstimulation. Curr Opin Obstet Gynecol, 2010; 22(4); 289-94. DOI: 10.1097/GCO.0b013e32833beebf.
Holzer, H., R. Casper and T. Tulandi. A new era in ovulation induction. Fertility and Sterility, 2006; 85(2); 277-284. DOI: 10.1016/j.fertnstert.2005.05.078.
Casper, R.F. and A.F.M. Mitwally. Use of the Aromatase Inhibitor Letrozole for Ovulation Induction in Women With Polycystic Ovarian Syndrome. Clinical Obstetrics and Gynecology, 2011; 54(4); 685-695. DOI: 10.1097/GRF.0b013e3182353d0f.
Shuling, L., M.L. Sie Kuei, S.E. Saffari, et al. Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility? Reprod Biomed Online, 2019; 38(1); 39-45. DOI: 10.1016/j.rbmo.2018.09.016.
Teede, H.J., M.L. Misso, J.A. Boyle, et al. Translation and implementation of the Australian-led PCOS guideline: clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Med J Aust, 2018; 209(S7); S3-S8. DOI: 10.5694/mja18.00656.
Rezk, M., A.E. Shaheen and I. Saif El-Nasr. Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial. Gynecol Endocrinol, 2018; 34(4); 298-300. DOI: 10.1080/09513590.2017.1395838.
Mejia, R.B., K.M. Summers, J.D. Kresowik, et al. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril, 2019; 111(3); 571-578 e1. DOI: 10.1016/j.fertnstert.2018.11.030.
Teede, H.J., M.L. Misso, M.F. Costello, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction, 2018; 33(9); 1602-1618.
Genazzani, A.D. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online, 2016; 33(6); 770-780. DOI: 10.1016/j.rbmo.2016.08.024.
Carlomagno, G. and V. Unfer. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci, 2011; 15(8); 931-6.
Crawford, T.J., C.A. Crowther, J. Alsweiler, et al. Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. Cochrane Database Syst Rev, 2015(12); CD011507. DOI: 10.1002/14651858.CD011507.pub2.
Balen, A.H., L.C. Morley, M. Misso, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update, 2016; 22(6); 687-708. DOI: 10.1093/humupd/dmw025.
Leao Rde, B. and S.C. Esteves. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics (Sao Paulo), 2014; 69(4); 279-93. DOI: 10.6061/clinics/2014(04)10.
Buhler, K. Managing infertility with the follitropin alfa prefilled pen injector - patient considerations. Ther Clin Risk Manag, 2015; 11; 995-1001. DOI: 10.2147/TCRM.S64222.
Yildiz, B.O. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2015; 100(3); 794-802. DOI: 10.1210/jc.2014-3196.
Xing, C., J. Zhang, H. Zhao, et al. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment. Int J Womens Health, 2022; 14; 91-105. DOI: 10.2147/IJWH.S344542.
When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement. Human Reproduction Open, 2019; 2019(3); hoz009.
Vannuccini, S., S. Clemenza, M. Rossi, et al. Hormonal treatments for endometriosis: The endocrine background. Rev Endocr Metab Disord, 2021. DOI: 10.1007/s11154-021-09666-w.
